Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats
- First Online:
- 249 Downloads
Doxorubicin (DXR) is an anthracycline glycoside with a broad spectrum of therapeutic activity against various tumors. However, the clinical use of DXR has been limited by its undesirable systemic toxicity, especially in the heart and kidney. This study was designed to test the effectiveness of dietary intake of pirfenidone (PD) against DXR-induced cardiac and renal toxicity.
Male Sprague Dawley rats were placed into four treatment groups: saline injected intraperitoneally (i.p.) plus regular diet (SA+RD); DXR i.p. plus regular diet (DXR+RD); saline i.p. plus the same diet mixed with 0.6% PD (SA+PD); and DXR i.p. plus the same diet mixed with 0.6% PD (DXR+PD). The animals were fed regular or regular plus PD diets 3 days prior to i.p. injections of either saline or DXR and continuing throughout the study. A total dose of DXR (16.25 mg/kg) or an equivalent volume of saline was administered in seven injections (2.32 mg/kg per injection) three times per week with an additional dose on the 12th day. At 25 days following the last DXR or saline injection, some animals were anesthetized for the measurement of cardiac and pulmonary function, and others were killed by an overdose of pentobarbital. At the time the animals were killed, abdominal fluid was collected. Kidney and heart were removed, weighed, fixed with 10% formalin or frozen in liquid nitrogen. The fixed tissues were used for histological examination and the frozen tissues were used for biochemical studies.
The average volumes of abdominal fluid in the DXR+RD and DXR+PD groups were 9.42 ml and 3.42 ml and the protein contents of abdominal fluid in the DXR+RD and DXR+PD groups were 218 mg and 70 mg, respectively. A 12.5% mortality occurred in the DXR+RD group as compared to 0% in DXR+PD group. There were no changes in any of the cardiac or pulmonary physiological parameters in any of the four groups. The changes in the heart and kidney of the DXR+RD group included reduction in organ weight, increase in hydroxyproline content of heart, increase in hydroxyproline, and lipid peroxidation in the kidney and plasma, and increase in protein concentration in urine as compared to rats in the control, SA+RD and SA+PD groups. Treatment with PD abrogated the DXR-induced increases in hydroxyproline content in the heart and kidney, lipid peroxidation of the kidney and plasma, and protein content of the urine in the DXR+PD group. DXR treatment alone caused disorganization of cardiac myofibrils, vacuolization of the myofibers, and renal tubular dilation with protein casts in both the cortical and medullary regions. Treatment with PD minimized the DXR-induced histopathological changes of heart and kidney in the DXR+PD group.
Treatment with PD reduced the severity of DXR-induced toxicity as assessed by reduced mortality, diminished volume of recovered fluid in the abdominal cavity, and severity of cardiac and renal lesions at both the biochemical and morphological levels. These results indicate that PD has the potential to prevent DXR-induced cardiac and renal damage in humans on DXR therapy.
KeywordsDoxorubicin Pirfenidone Antioxidant Heart Kidney
- 4.Barchowsky A, Dudek EJ, Treadwell MD, Wetterhan KE (1996) Arsenic induces oxidant stress and NF-kB activation in cultured aortic endothelial cells. Free Radic Biol Med 18:321Google Scholar
- 7.Blum RH (1975) An overview of studies with Adriamycin (NSC) in the United States. Cancer Chemotherapy Rep 6:247Google Scholar
- 8.Bristow MR (1982) Toxic cardiomyopathy due to doxorubicin. Hosp Pract 17:101Google Scholar
- 10.Bus JS, Gibson JE (1979) Lipid peroxidation and its role in toxicology. In: Hodgson E, Bend JR, Philpot RM (eds) Reviews in biochemical toxicology. Elsevier North Holland, New York, p 125Google Scholar
- 12.Chabner BA, Ryan DP, Paz-Ares L, Carbonero RG, Calabresi P (2001) Antineoplastic agents. In: Hardman JG, Limbird LE, Gilman AG (eds) Goodman and Gilman’s the pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York, p 1389Google Scholar
- 17.Giri SN, Leonard S, Shi X, Margolin SB, Vallyathan V (1999) Effects of pirfenidone on the generation of reactive oxygen species in vitro. J Environ Pathol Toxicol Oncol 18:169Google Scholar
- 23.Hinshaw L, Olson P, Kuo G (1989) Efficacy of post-treatment with anti-TNF monoclonal antibody in preventing the pathophysiology and lethality of sepsis in the baboon. Circ Shock 27:362Google Scholar
- 30.Kojima S, Icho T, Hayashi M, Kajiwara Y, Kitabatake K, Kubota K (1993) Inhibitory effect of 5,6,7,8-tetrahydroneopterin on adriamycin-induced cardiotoxicity. J Pharmacol Exp Ther 266:699Google Scholar
- 33.Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with Folin phenol reagent. J Biol Chem 193:265Google Scholar
- 35.McManus JFA, Mowry RW (1960) Staining methods, histologic and histochemical. Paul B. Hoeber, Medical Division of Harper and Brothers, New York, p 223Google Scholar
- 36.Minotti G, Ronci R, Salvatorelli E, Menna P, Cairo G (2001) Doxorubicin irreversibly inactivates iron regulatory protein 1 and 2 in cardiomyocytes: evidence from distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 61:8422PubMedGoogle Scholar
- 41.Ohkawa H, Ohismi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Biochemistry 95:351Google Scholar
- 45.Sun Y, Oberley LW (1966) Redox regulation of transcriptional activators. Free Radic Biol Med 21:335Google Scholar
- 46.Tada S, Nakamuta M, Enjoji M (2001) Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Exp Pharmacol Physiol 133:687Google Scholar
- 47.Tracy KJ, Beutler B, Lowry SF, et al (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234:470Google Scholar
- 48.Woessner JF Jr (1961) The determination of hydroxyproline in tissue and protein samples containing small proportions of this amino acid. Arch Biochem Biophys 93:440Google Scholar